Rogier Mous

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

Journal: European journal of haematology
Published: April 27, 2026

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA.

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA.

Journal: Blood advances
Published: October 24, 2025

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.

Journal: Cell reports. Medicine
Published: June 30, 2025

Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP.

Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP.

Journal: Blood advances
Published: November 01, 2024

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Journal: Blood advances
Published: October 25, 2024

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study.

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study.

Journal: American journal of hematology
Published: August 08, 2023

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA.

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA.

Journal: Journal of hematology & oncology
Published: July 26, 2023

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.

Journal: Blood cancer journal
Published: January 27, 2023

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Journal: Leukemia & lymphoma
Published: June 23, 2022

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.

Journal: Cancers
Published: February 11, 2022

Hematologic malignancies following immune checkpoint inhibition for solid tumors.

Hematologic malignancies following immune checkpoint inhibition for solid tumors.

Journal: Cancer immunology, immunotherapy : CII
Published: February 06, 2022

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology
Published: February 05, 2022
Showing 1-12 of 23

Last Updated: 09/26/2026